Compare Mesoblast Limited (MESO) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while YieldMax NVDA Option Income Strategy ETF trades at $12.77 (market cap $1.45B). The key difference: Mesoblast Limited is the larger of the two by market cap, and YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| MESO | NVDY | |
|---|---|---|
Market Cap | $1.75B | $1.45B |
Volume | 239,027 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $20.96 | $17.21 |
52-Week Low | $13.19 | $11.58 |
Typical Hold Time | 14 Days | 43 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $13.01, down slightly by 0.31% on the day. The technical outlook is bullish based on moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The fund generates weekly dividend distributions, with recent payouts ranging from $0.08 to $0.12, but faces criticism for potential net asset value erosion and capped upside participation relative to its underlying asset, NVIDIA stock.
The outlook for NVDY is mixed; it offers high distribution yields but structural limitations may hinder long-term capital appreciation. Investment opportunities include income generation in a low-volatility environment, while risks involve NAV erosion and reduced upside capture if NVIDIA's volatility declines. Analyst sentiment has shifted to hold ratings, reflecting concerns over sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
